Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q1 2022 Earnings Conference Call May 11, 2022 8:30 AM ET

Company Participants

Allison Wey - SVP, IR & Corporate Communications

Paul Edick - Chairman & CEO

Steve Pieper - CFO

Conference Call Participants

David Amsellem - Piper Sandler

Roanna Ruiz - SVB Securities

Vamil Divan - Mizuho Securities

Robin Garner - Craig-Hallum

Oren Livnat - H.C. Wainwright

Operator

Hello, and welcome to today’s Xeris Biopharma’s First Quarter 2022 Financial Results Conference Call and Webcast. My name is Bailey and I will be your moderator for today’s call. All lines will be muted during the presentation portion of the call, with an opportunity for questions-and-answers at the end. [Operator Instructions]

I would now like to pass the conference over to Allison Wey, Senior Vice President of Investor Relations and Corporate Communications. Allison, please go ahead.

Allison Wey

Thank you, Bailey. Good morning and welcome to Xeris Biopharma's first quarter 2022 financial results and corporate update conference call and webcast. A press release with the company's first quarter 2022 financial results was issued earlier this morning and can be found on our website. We are joined this morning by Paul Edick, Chairman and CEO; and Steve Pieper, our CFO. Paul will provide opening remarks, Steve will provide details on our financial results and then, we will open up the call for questions.

Before we begin, I would like to remind you that this call will contain forward-looking statements concerning Xeris' business practices, Xeris' future expectations, plans, prospects, clinical approvals, commercialization, corporate strategy, performance, and the impact of COVID-19 on Xeris' business practices, which constitute forward-looking statements for the purposes of the Safe Harbor provision under the Private Securities Litigation Reform Act of 1995.

Actual results may differ materially from those indicated by these forward-looking statements, as a result of various important factors, including the effect of uncertainties related to the COVID-19 pandemic on the U.S. and global markets, Xeris' business, financial condition, operations, clinical trials and third-party suppliers and manufacturers and other risk factors included those discussed in our filings with the SEC.

In addition, any forward-looking statements represent our views only as of the date of this call and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligations to update such statements.

I'll now turn the call over to Paul.

Paul Edick

Thanks, Allison. Good morning to everybody and thanks for joining us today. Our headline for this call is that we had another very good quarter in the first quarter of 2022. We generated approximately $22 million in net product revenue. We continued strong prescription and share growth for Gvoke.